Rituximab

Red

Brand Name(s):

Indication:Delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies

Rationale:1,2,8

Considered:Nov-20

Review Date:Nov-25

Comments:
Rituximab is recommended to be available as a treatment option through routine commissioning for delayed haemolytic transfusion reactions and hyperhaemolysis in patients with haemoglobinopathies.